Heart failure (HF) with preserved left ventricular (LV) ejection fraction (HFpEF) represent today the largest 'unmet medical need', because none of the drugs presently available improved survival in this consistent proportion of patients with HF, ~50% of the total, who have an LV ejection fraction ≥50%. Heart failure with preserved left ventricular ejection fraction is a clinical syndrome that in its classical form, is associated to typical risk factors and comorbidities. The comorbidities represent one of the element contributing to the extreme heterogeneity which characterizes HFpEF. The pathophysiological mechanisms, as well as the clinical presentation, are multifaceted. These factors explain, by and large, the failure of a generalized therapeutic strategy, while build the argument for personalized medicine, designed to address the specific phenotypes, with therapies proven in specific subgroups of patients with HFpEF to reduce mortality and improve 'surrogate' outcomes, such as quality of life.

Gori, M., D'Elia, E., Iorio, A., Iacovoni, A., & Senni, M. (2020). Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction. EUROPEAN HEART JOURNAL SUPPLEMENTS, 22, L124-L128 [10.1093/eurheartj/suaa151].

Clinical application of personalized medicine: Heart failure with preserved left ventricular ejection fraction

Senni M
2020

Abstract

Heart failure (HF) with preserved left ventricular (LV) ejection fraction (HFpEF) represent today the largest 'unmet medical need', because none of the drugs presently available improved survival in this consistent proportion of patients with HF, ~50% of the total, who have an LV ejection fraction ≥50%. Heart failure with preserved left ventricular ejection fraction is a clinical syndrome that in its classical form, is associated to typical risk factors and comorbidities. The comorbidities represent one of the element contributing to the extreme heterogeneity which characterizes HFpEF. The pathophysiological mechanisms, as well as the clinical presentation, are multifaceted. These factors explain, by and large, the failure of a generalized therapeutic strategy, while build the argument for personalized medicine, designed to address the specific phenotypes, with therapies proven in specific subgroups of patients with HFpEF to reduce mortality and improve 'surrogate' outcomes, such as quality of life.
Articolo in rivista - Articolo scientifico
Heart failure with preserved left ventricular ejection fraction; Phenotype; Therapeutic personalization;
English
L124
L128
Gori, M., D'Elia, E., Iorio, A., Iacovoni, A., & Senni, M. (2020). Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction. EUROPEAN HEART JOURNAL SUPPLEMENTS, 22, L124-L128 [10.1093/eurheartj/suaa151].
Gori, M; D'Elia, E; Iorio, A; Iacovoni, A; Senni, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372912
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
Social impact